7-Eleven names new marketing agency of record
7-Eleven has named media and marketing company UM as its media agency of record, according to a Friday announcement from the agency.
UM, which is owned by IPG Mediabrands, will be responsible for full-funnel, cross-channel media strategy as well as digital media activation for 7-Eleven, Speedway and the 7Now app.
The retailer will utilize UM's 'Full Color Media' media planning proposition, released earlier this year, which seeks to use vibrancy, distinction. and cultural relevance to make a brand stand out from the crowd. Its model analyzes the relationship between brand perceptions over time and how such perceptions impact business results, then applies that data to forward-looking marketing strategies.
"By leveraging UM's unique data-enabled approach, we are poised to unlock new opportunities to bring more people to our stores and ensure 7-Eleven remains an essential part of their daily lives,' said Marissa Jarratt, executive vice president and chief marketing and sustainability officer for 7-Eleven, in the announcement.
7-Eleven is coming off a year in which its 'Always Open' advertising campaign with professional football player JaMarr Chase won multiple awards. 7-Eleven is still working with Dentsu, according to information from the company.
Representatives from 7-Eleven could not be reached by press time to confirm if UM was replacing Dentsu Creative.
In addition to 7-Eleven, UM's clients include well-known brands American Express, Levi Strauss, Dyson and Mattel.
Editor's note: This story was updated to add additional information from 7-Eleven.
Recommended Reading
7-Eleven refreshes Slurpee with 'Anything Flows' campaign
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Journals
3 hours ago
- Business Journals
Walker's Point machine shop site eyed for 300 apartments
C-Suite Stars & Executive of the Year The Milwaukee Business Journal is accepting nominations for its C-Suite Stars and Executive of the Year awards, which recognize the work of corporate leaders in a range of functions.
Buzz Feed
3 hours ago
- Buzz Feed
Trump's Math Fail Sparks Massive Online Trolling
President Donald Trump is getting heat on social media for making a claim on Tuesday about cutting drug prices that's essentially mathematically impossible. Trump began promisingly enough with a complaint shared by Democrats and Republicans alike: the high cost of medication, and how much more Americans pay for some medications than patients in other countries. He promised to reduce those costs ― but to a very unlikely degree. 'We're gonna get the drug prices down. Not 30% or 40%, which would be great. Not 50% or 60%. No, we're gonna get them down 1,000%, 600%, 500%, 1,500%,' Trump said at a Republican dinner. 'Numbers that are not even thought to be achievable.' Critics quickly pointed out the reason those numbers are not thought to be achievable: reducing the price by 100% would make the drugs free. Reducing it by '1,000%, 600%, 500%, 1,500%,' as Trump said, would make the cost negative dollars ― with the drug company essentially paying people to take the medication. Trump: This is somebody nobody else can do. I can get the drug prices down… 1000% 600% 500% 1500%. Numbers that are not even thought to be achievable. — Acyn (@Acyn) July 23, 2025 @acyn/ C-SPAN / Via Twitter: @Acyn Several users asked Grok, the AI chatbot on X, if Trump's numbers made sense. Grok called Trump's claim ' mathematically impossible,' ' hyperbolic and not literal ' and ' total bullshit.' But Trump insisted he could use 'a certain talent that I have' to convince pharmaceutical companies that they have no choice but to reduce their prices. Trump also mentioned an executive order he signed in May to invoke 'most-favored nation' status in drug costs, which he says would ensure that drug companies can't charge Americans any more than what they charge patients in other nations. However, the details of that plan remain hazy, and at least one pharmaceutical CEO said discussions with the White House are ongoing and expected to take time. Trump on Tuesday insisted that his order will lead to those price cuts. 'We will have reduced drug prices by 1,000%, by 1,100, 1,200, 1,300, 1,400, 700, 600,' he said. 'Not 30 or 40 or 50%, but numbers the likes of which you've never even dreamed of before.' Trump's critics offered some free math lessons: As someone who graduated from first grade, this is not how numbers work. — Hemant Mehta (@hemantmehta) July 23, 2025 @hemantmehta/ C-SPAN Thank goodness this guy isn't negotiating the percentages we pay in tariffs. — Justin Wolfers (@JustinWolfers) July 23, 2025 @justinwolfers / C-SPAN Quite a trick if he can do it. Are we going into negative numbers where big Pharma pays me to take their drugs? — Dj Omega Mvp (@DjOmegaMVP) July 23, 2025 @DJOmegaMVP/ C-SPAN Hard to imagine this guy was found liable of fraud for making up numbers — MeidasTouch (@MeidasTouch) July 23, 2025 @meidastouch/ C-SPAN So the drug companies are going to pay us to take their drugs? Dumbest President EVER. — SickoftheCrap (@SickoftheC) July 23, 2025 @SickoftheC The economics department at Wharton must be incredibly proud of this man's fundamental understanding of basic math. — Franklin Leonard (@franklinleonard) July 23, 2025 @franklinleonard/ C-SPAN Cant wait fill my next zpack at cvs and leave with a stack of their money — Ronnie (@Gem_Mint_Cards_) July 23, 2025 @gem_mint_cards_/ C-SPAN I feel like a requirement of being president should be understanding basic math. — Jared Ryan Sears (@JaredRyanSears) July 23, 2025 @JaredRyanSears So medicines would be free and pharmaceutical companies would pay us? — Bru🔮 💉🗣 (@brwninh4) July 23, 2025 @brwninh4 Getting paid to take drugs sounds awesome where do I sign up — TCL (@TitleTalkTCL) July 23, 2025 @titletalkTCL / C-SPAN Universal Prescription Income. Your move, Yang — Roger Sollenberger (@SollenbergerRC) July 23, 2025 @SollenbergerRC/ C-SPAN What kind of math is this? — Wu Tang is for the Children (@WUTangKids) July 23, 2025 @WuTangKids/ C-SPAN And people wonder how this idiot bankrupted casinos. — Jo (@JoJoFromJerz) July 23, 2025 @JoJoFromJerz/ C-SPAN Negative drug prices are on the way ! 🤣🇺🇸 — Christopher Schultz (@nalyticsatwork) July 23, 2025 @nalyticsatwork/ C-SPAN This is the fucking genius. — Fred Wellman (@FPWellman) July 23, 2025 @FPWellman/ C-SPAN — Dave Itzkoff (@ditzkoff) July 23, 2025 @DaveItzkoff/ C-SPAN @realDonaldTrump is out here pitching drug deals like it's Shark Tank for Cartels: 'I'm offering insulin for negative $300 and a lifetime supply of bleach injections… but only if you call in the next 15 minutes.' This QVC for crackheads. — Frank C (@FrankC164) July 23, 2025 @FrankC164/ C-SPAN
Hamilton Spectator
8 hours ago
- Hamilton Spectator
Seven & i pushes back against Couche-Tard's reasons for deal talks ending
The parent company of 7-Eleven has pushed back against the reasons Alimentation Couche-Tard Inc. gave for why a takeover deal never materialized. Couche-Tard said last week that it was ending a yearlong effort to buy Seven & i Holdings Co. Ltd., saying there had been no sincere or constructive engagement from the Japan-based company over a potential deal. Seven & i's special board committee said in a letter issued Tuesday that Couche-Tard made 'highly misleading' claims as it ended its efforts, and that Seven & i consistently engaged in good faith. It says that from the start, Couche-Tard didn't take competition concerns seriously, and didn't present a credible plan as to how those concerns would be addressed. Given the scale of the two convenience store chains, Seven & i noted that regulators would likely require they make a 'very significant divestiture' before approving a deal, but Couche-Tard was not able to provide a plan on who could be the buyer or how such a deal would work. Seven & i also pushed back against the characterization that its governance was not up to the task, and suggested that Couche-Tard perhaps did not properly understand the Japanese market. This report by The Canadian Press was first published July 23, 2025. Companies in this story: (TSX:ATD)
